Cohort Study: SLGT2 Inhibitors Linked to Lower Risk of Renal Events in Patients with Type 2 Diabetes
7 May, 2020 | 08:57h | UTCEditorial: SGLT2 inhibitors and kidney outcomes in the real world
Commentary: Certain diabetes drugs may protect against serious kidney problems – The BMJ
Related Analysis: Communicating emerging risks of SGLT2 inhibitors—timeliness and transparency of medicine regulators – The BMJ